The prognostic and therapeutic values of long noncoding RNA PANDAR in colorectal cancer

Rivandi, Mahdi; Pasdar, Alireza; Hamzezadeh, Leila; Tajbakhsh, Amir; Seifi, Sima; Moetamani‐Ahmadi, Mehrdad; Ferns, Gordon A.; Rezayi, Majid

doi:10.1002/jcp.27136

Cited by 20 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Besides, the value of lncRNAs in cancer diagnostics, prognostics, and therapeutics has been recognized. 19,20 The ceRNA hypothesis holds that lncRNAs could serve as sponge of target miRNAs. This sets a new direction for the research on tumor diagnosis, prognosis, and targeted treatment.…”

Section: Rt-qpcr Of Candidate Lncrnasmentioning

confidence: 99%

Competing endogenous RNA network of endometrial carcinoma: A comprehensive analysis

Liu

Nie

Liang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Competing endogenous RNA (ceRNA) network is dysregulated in the initiation and progression of tumors. In the present study, we explored the regulatory mechanism of ceRNA in endometrial carcinoma (EC) and the potential key molecules with potential value in the diagnosis, treatment, and prognosis of EC. The long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) expression profiles (552 EC tissues and 35 nontumor tissues) and microRNAs (miRNAs) expression profiles (546 EC tissues and 33 nontumor tissues) were downloaded from The Cancer Genome Atlas database to identify differentially expressed RNAs (DERNAs) in EC. An integrated bioinformatics analysis was used to construct an EC‐specific ceRNA network and select key molecules. As a result, 96 differentially expressed lncRNAs (DElncRNAs), 29 differentially expressed miRNAs (DEmiRNAs), and 77 differentially expressed mRNAs (DEmRNAs) were identified. An EC‐specific ceRNA network was built based on nine DElncRNAs significantly associated with overall survival. CCNB1 was found as a key gene in EC through the weighted gene coexpression network analysis and protein‐protein interaction network analysis. Our ceRNA network showed C2orf48 and LINC00483 might upregulate CCNB1 via competing with miR‐183. In addition, we found a subnetwork which contained survival‐associated DERNAs (AC110491.1, LINC00483‐miR‐192‐GRHL1). The results of reverse transcription quantitative polymerase chain reaction supported the relative expressions of C2orf48, LINC00483 were upregulated and that of AC110491.1 was downregulated in EC. We further found C2orf48 was upregulated in serous EC, endometrioid EC, and mixed serous and endometrioid EC. LINC00483 was upregulated in mixed serous and endometrioid EC compared with that in the normal tissues according to UALCAN database. In addition, candidate small molecular drugs were screened out by ConnectivityMap based on the 77 DEmRNAs in the ceRNA network. Eventually, C2orf48, LINC00483, and AC110491.1 were identified as three key lncRNAs in EC.

show abstract

Section: Rt-qpcr Of Candidate Lncrnasmentioning

confidence: 99%

Competing endogenous RNA network of endometrial carcinoma: A comprehensive analysis

Liu

Nie

Liang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…LncRNA PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) has been reported to be overexpressed in cancer tissues and associated with poor prognosis in many types of human cancer, including colorectal cancer,37 renal cell carcinoma,38 and bladder cancer;39 while in lung cancer the correlation of PANDAR is found to be opposite.40 In gastric cancer, PANDAR could promote the malignant progression by regulating CDKN1A gene transcription in a p53-dependent manner.11 LncRNA FOXD2-AS1 might play important roles in kinds of cancer like glioma,41 colorectal cancer.42 It has been found that upregulation of FOXD2-AS1 could promote carcinogenesis and predict poor prognosis in gastric cancer both in vitro and in vivo. Cell cycle and DNA-replication-related genes should be involved in FOXD2-AS1 function.…”

Section: Discussion/conclusionmentioning

confidence: 99%

<p>Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer</p>

Yang

Sun

Rong-feng

et al. 2019

CMAR

View full text Add to dashboard Cite

Background Gastric cancer is still a common cancer worldwide. Investigation of potential plasma biomarkers for gastric cancer diagnosis is essential for prevention strategies and early intervention for gastric cancer-control planning. Objectives This study was aimed to explore the lncRNAs' promoter of CDKN1A antisense DNA-damage-activated RNA (PANDAR), FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer. Method 109 gastric cancer patients and 106 healthy controls were involved in this study. Plasma lncRNAs PANDAR, FOXD2-AS1, and SMARCC2 were detected by real-time PCR. Student’s t -test, Mann-Whitney U test, and Chi-square test were used to verify the differences of clinical variables between two groups. Receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of every biomarker. Multivariable analysis of risk factors for gastric cancer was performed using logistic regression analysis. Results There were significant differences in age, gender, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 153 between gastric cancer and healthy controls ( P <0.05). Compared with healthy subjects, the levels of plasma lncRNAs PANDAR, FOXD2-AS1, and SMARCC2 were all significantly higher in gastric cancer patients ( P <0.05). These lncRNAs were significantly associated with clinicopathological parameters of gastric cancer, like pathological differentiation, TNM stage, and/or lymph nodes metastasis, and/or invasion depth ( P <0.05). The AUC for lncRNA PANDAR was 0.767, for FOXD2-AS1 was 0.700, for SMARCC2 was 0.748, and the AUC of the combinative diagnostic value of these three lncRNAs was 0.839. Adjusted by other variables, these lncRNAs' expressions were significantly associated with gastric cancer. Conclusions Plasma lncRNAs PANDAR, FOXD2-AS1, and SMARCC2 might be appropriate diagnostic biomarkers for gastric cancer.

show abstract

“…The study also found that high expression of PANDAR may represent a new prognostic marker for patients with CRC. Based on previous studies, the overexpression of PANDAR in CRC, breast cancer, and other tissues is related to the decrease in oxygen saturation, indicating its potential as a biomarker of poor prognosis ( Rivandi et al, 2019 ).…”

Section: General Application Of Rnaimentioning

confidence: 96%

Insight Into the Prospects for RNAi Therapy of Cancer

et al. 2021

View full text Add to dashboard Cite

RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development.

show abstract

The prognostic and therapeutic values of long noncoding RNA PANDAR in colorectal cancer

Cited by 20 publications

References 31 publications

Competing endogenous RNA network of endometrial carcinoma: A comprehensive analysis

Competing endogenous RNA network of endometrial carcinoma: A comprehensive analysis

<p>Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer</p>

Insight Into the Prospects for RNAi Therapy of Cancer

Contact Info

Product

Resources

About